ALNY

ALNYLAM PHARMACEUTICALS, INC.

NasdaqHealthcarePHARMACEUTICAL PREPARATIONS

Insider activity for last month from Oct 16 to Nov 16.

How these metrics are calculated

Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Total buying$543k2 buys
Total selling$00 sales
Net open-market+$543kBuying minus selling
Active insiders3Distinct reporting owners

ALNY transaction history

Newest filings · 20 transactions per page

Latest insider transactions

Form 4 filings from last month.
Newest company filings
InsiderActivityDisclosed valueFiled (ET)
Pyott David E I
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
Pyott David E I
Director
DIR
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
SEC filing ↗
$272kView disclosure →
Sigal Charles Elliott
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Cluster buy
At least two distinct reporting owners bought within 14 days, with combined known value of at least $100k.
Director buy
The buyer is identified as a director.
+1
Large acquisition

Units acquired were at least 25% of reported post-transaction holdings.

SEC filing ↗
$244kView disclosure →
Schulman Amy W
Director
DIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Director buy
The buyer is identified as a director.
SEC filing ↗
$300kView disclosure →

Insider activity report

Calendar-month buckets within the selected date range

Latest filing: Nov 12, 2026

Open-market transaction mix · 2 transactions in the selected period
2 buys100%·0%0 sells

Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.

View exact monthly counts and disclosed values
Monthly activity within the selected period; unknown values remain unknown.
MonthBuysSellsAwards (A)Buy valueSell valueNet P/S value
Oct 2026000$0$0$0
Nov 2026200$543,126.20$0+$543,126.20

Distinct insiders active

Reporting-owner CIKs by month · peak Nov 2026 (3)
Oct 2026: 0 insidersNov 2026: 3 insiders
Oct 2026Nov 2026
3distinct insiders in selected period
Largest insider activity
By absolute net disclosed value · current transaction page
3 insiders
Filing, role and holdings details

Filing-only signals

Deterministic matches in the selected period

Recent filing activity
Most recent 4 transactions on this page · color = transaction code

Filing detail checks

Secondary metrics for the selected period
Largest buy$300k
Largest sale—
10b5-1 detected0
Amended rows0

Transaction codes

By Form 4 transaction code in selected period
4transactionstxns
  • M · Option exercise · dominant2 · 50%
  • P · Open-market buys2 · 50%

Activity by reported role

A joint filing can contribute to multiple roles
Director4

Reported Holdings After

Separated by insider, security, and ownership type

Schulman Amy WCommon Stock · Direct
26.0k26.0kNov 9, 2026Nov 9, 2026
25,959Nov 9, 2026
Sigal Charles ElliottCommon Stock · Indirect · by Trust
3.60k3.60kNov 10, 2026Nov 10, 2026
3,600Nov 10, 2026
Pyott David E ICommon Stock · Direct
5.36k5.36kNov 10, 2026Nov 10, 2026
5,362Nov 10, 2026
Pyott David E IStock Option (Right to Buy) · Direct
00Nov 10, 2026Nov 10, 2026
0Nov 10, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells red
1 active days
Oct 16 → Nov 16
LessMore

ALNYLAM PHARMACEUTICALS, INC. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at ALNYLAM PHARMACEUTICALS, INC.?

PYOTT DAVID E I, Sigal Charles Elliott, SCHULMAN AMY W.

When was the latest reported open-market purchase?

Sigal Charles Elliott reported a buy on Nov 10, 2026 valued at $244k. Read the SEC filing.

When was the latest reported open-market sale?

No code-S sale is available for this period.

What is the recent purchase and sale balance?

Net open-market buying in the selected period was $543,126.20.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.